Formosa Laboratories, Inc. · TWSE:4746
Formosa Laboratories — Investor Presentation (August 2025)
21 slides from Formosa Laboratories's investor presentation, Aug 15, 2025
Slide 1: August 15, 2025 TWSE 4746
August 15 , 2025 TWSE 4746 2025/8/15 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by Formosa Laboratories Inc. (“Formosalab”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herei
Slide 3: 2024 & 2025 up-to-July Operation Results, Business Strategy, Business Update
• 2024 & 2025 up-to-July Operation Results • Business Strategy • Business Update 2025/8/15 3
Slide 4: Operation Results
Operation Results 2025/8/15 4
Slide 5: Revenues 2025 up to July YoY 3%
Revenues 2025 up to July YoY 3% 5,000 8% 4,731 4,360 4,000 3,766 3,075 3,142 3,000 3% 2,763 2,676 2,000 1,000 - 2020 2021 2022 2023 2024 2024 up to 2025 up to July July Million NTD 2025/8/15 5
Slide 6: Revenues 2025 up to July YoY 3%
Revenues 2025 up to July YoY 3% Million NTD YoY Polymers 956 0% Vit. D Derivatives 421 14% Steroids 368 251% Respiratory Agents 306 -8% CDMO 255 -4% Anticancers 188 45% Others 268 -48% Total 2,763 3% 2025/8/15 6
Slide 7: Product Category
Product Category Polyermers Vit. D Derivatives Steroids Respiratory Agents CDMO Anticancers Inflammation Immunomodulator Others 9% 6% 13% 9% 12% 2% 2% 3% 3% 5% 2% 7% 5% 6% 4% 6% 3% 6% 4% 9% 3% 16% 12% 10% 11% 14% 11% 12% 9% 13% 6% 1% 0% 1% 3% 19% 19% 19% 17% 15% 33% 34% 36% 35% 35% 2021 2022 2023 20
Slide 8: 2025 1H Profitability
2025 1H Profitability EPS NTD -0.25 BV per share NTD 60.64 50% 44% 42% 42% 39% 40% 37% 31% 30% 22% 20% 20% 20% 14% 11% 10% 6% 3% 3% 0% -1% -10% Gross Margin Operating Margin Net Margin 2025/8/15 8
Slide 9: 2024Q2~2025Q2 Profitability
2024Q2~2025Q2 Profitability 45% 43% 42% 41% 41% 42% 35% 25% 25% 23% 22% 23% 22% 20% 22% 21% 19% 19% 16% 15% 11% 5% 2% -5% -4% -15% -12% Net Operating Margin Operating Profit Income after Tax Operating Expenses 2025/8/15 9
Slide 10: Business Strategy
Business Strategy 2025/8/15 10
Slide 11: Integrated RD and Manufacturing
Integrated RD and Manufacturing - High quality GMP manufacturing - DS to DP one stop - Supply chain service management - ADC - Effective output to - Peptide fulfill demand CDMO Generic API - Formulation development - Clinical and commercial Injectable manufacturing - Product development and license-
Slide 12: Diversified Alliance to Explore Business Opportunity
Diversified Alliance to Explore Business Opportunity Biologics API ADC Injectable CDMO ADC Nano-tech HPAPI API ADC CDMO 2025/8/15 12
Slide 13: Expand Oversee Footprint and Market
Expand Oversee Footprint and Market 2025/8/15 13
Slide 14: Key Business
Key Business 2025/8/15 15
Slide 15: Key API Products
Key API Products • Improve throughput • Expand manufacture capacity • Stable supply chain Highlight • Polymer API stay strong market share. • New vit. D derivatives starts commercial supply and contribute to revenue. • Anti-cancer and steroid products steadily deliver to clients. 2025/8/15 16
Slide 16: Comprehensive CDMO Service-One Stop Shop
Comprehensive CDMO Service-One Stop Shop API/DS Labelling/ CMC Injectable Research Packaging/ Development Manufacturing Manufacturing Logistics • One-stop service requests increase up to 30% including APAC, EU, and US. • Stable CMO supply to originator in Japan, Europe, and US. • Synchem-Formosa sta
Slide 17: Once stop ADC services
Once stop ADC services Service scope • Linker-payload, Bioconjugation, and process development • ADC candidate screening platform • Scale-up manufacturing. ADC-DS new line completes validation. The new line can support upto commercial scale supply • Comprehensive analytic services ADC CDMO highlight
Slide 18: Injectable Plant Status
Injectable Plant Status • Authority inspection is ongoing • Cytotoxic line - TFDA: 2022Q2 completed - FDA: passed first FDA on-site GMP inspection held in July 2024. - EMA: passed first EMA on-site GMP inspection held in May 2025 • General line - TFDA: 2024/08 completed inspection. Receive GMP certi
Slide 19: Self-development Injectable Products
Self-development Injectable Products Eribulin Injectable (Global market size USD 370 million, US Market USD 130 million, EU market USD 80 million, TW market NTD 450 million) Territory Status Taiwan Hospital listing keeps going. Already started deliver. Get the first Taipei city hospital joint tend
Slide 20: Self-development Injectable Products
Self-development Injectable Products Other self-development injectable products are ongoing - Anemia - GLP-1 Products - Chronic kidney disease related 2025/8/15 22
Slide 21: Q&A
Q&A 2025/8/15 23
Formosa Laboratories — Investor Presentation (August 2025) on 6ix